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ABSTRACT: Asthma is characterised by airway hyperreactivity, which is primarily treated with b-
adrenergic bronchodilators and anti-inflammatory agents. However, mechanical strain during
breathing is an important modulator of airway responsiveness and we have previously
demonstrated in animal models that continuous positive airway pressure (CPAP) resulted in
lower in vivo airway reactivity. We now evaluated whether using nocturnal CPAP decreased airway
reactivity in clinically-stable adults with asthma.
Adults with stable asthma and normal spirometry used nocturnal CPAP (8–10 cmH2O) or sham
treatment (0–2 cmH2O) for 7 days. Spirometry and bronchial challenges were obtained before and
after treatment. The primary outcome was the provocative concentration of methacholine causing
a 20% fall in forced expiratory volume in 1 s (PC20).
The CPAP group (n516) had a significant decrease in airway reactivity (change in (D)logPC20
0.406, p,0.0017) while the sham group (n59) had no significant change in airway reactivity
(DlogPC20 0.003, p50.9850). There was a significant difference in the change in airway reactivity
for the CPAP versus the sham group (DlogPC20 0.41, p,0.043).
Our findings indicate that chronic mechanical strain of the lungs produced using nocturnal
CPAP for 7 days reduced airway reactivity in clinically stable asthmatics. Future studies of longer
duration are required to determine whether CPAP can also decrease asthma symptoms and/or
medication usage.
KEYWORDS: Bronchial challenge, chronic mechanical strain, continuous positive airway
pressure, lung function
A
sthma, which is characterised by repeated
episodes of reversible airway obstruction,
airway hyperreactivity and airway inflam-
mation, is primarily treated with b-adrenergic
bronchodilators and anti-inflammatory agents.
These therapies are effective in the prevention of
symptoms for the vast majority of asthmatics;
however, they are limited by high cost, poor
adherence and increasing concern about long-term
adverse effects. Thus, there is a compelling need
for new, safe and effective approaches to the treat-
ment of asthma. The mechanical strain imposed
on the lungs during breathing is an important
modulator of airway responsiveness in vivo [1].
Deep inspirations and tidal breathing decrease
airway responsiveness in healthy adults and
animals, while the absence of a deep inspiration
or tidal breathing increases airway responsiveness
[2–6]. However, in humans, the bronchoprotec-
tive effect of acute mechanical strain lasts for only
10–20 min and it is less effective in patients with
asthma [3, 4].
The application of chronic mechanical strain to
airway tissues in vitro has also been shown to
induce changes in their active and passive physio-
logical properties [7, 8]. Using in vivo animal
models, our laboratory has demonstrated that
chronic mechanical strain of the lung produced
by continuous positive airway pressure (CPAP)
can result in lower airway reactivity in vivo and in
vitro [9, 10]. We recently reported that the admin-
istration of high CPAP (6 cmH2O) to rabbits for
4 days followed by 1 day of low CPAP (0 cmH2O)
resulted in a persistent reduction of in vivo airway
responsiveness compared with rabbits treated
with low CPAP for 5 days [11]. In addition, the
positive effects of high CPAP in rabbits could also
be obtained by using only nocturnal high CPAP for
the same time period [11]. Lastly, chronic high
CPAP also suppressed in vivo airway reactivity in
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the presence of allergic airway inflammation, rabbits sensitised
and challenged with ovalbumin [11]. As the pre-clinical studies
suggested that nocturnal CPAP might decrease airway reactivity
in patients with asthma, we hypothesised that the use of
nocturnal CPAP for 7 days by clinically stable patients with
asthma would decrease airway reactivity.
METHODS
Subjects
Adults with clinically stable asthma were recruited to partici-
pate in the study. Subjects were recruited from the database
maintained by the Asthma Clinical Research Center at Indiana
University (Indianapolis, IN, USA), from clinics at Indiana
University and by local advertisements.
Inclusion criteria were: 1) physician-diagnosed asthma; 2) forced
expiratory volume in 1 s (FEV1) .70% predicted; 3) .15%
increase in FEV1 following an inhaled bronchodilator; 4)
clinically stable asthma with Juniper score ,1.5 [12]; and 5)
provocative concentration of methacholine causing a 20% fall in
FEV1 (PC20) ,16 mg?mL-1. Exclusion criteria were: 1) smoking
cigarettes or cigars; 2) acute respiratory illness or use of systemic
corticosteroids in the previous 2 months; 3) gastro-oesophageal
reflux requiring medical management, chronic obstructive
pulmonary disease, ischaemic heart disease or hypertension
requiring treatment with medications other than diuretics; and 4)
Berlin Questionnaire for sleep apnoea with a positive score
in two or more categories [13].
The study was approved by the Indiana University Institutional
Review Board and informed written consent was obtained from
all subjects.
Study design
The primary objective of the study was to determine whether
CPAP treatment produced a greater decrease in airway
reactivity assessed by methacholine (MCh) challenge compared
with sham treatment in adults with stable asthma. At a screening
visit to determine eligibility, an Asthma Score (Juniper) was
obtained to determine clinical stability; subjects were included
only if the score was f1.5 [12]. In addition, to minimise the
inclusion of subjects with obstructive sleep apnoea (OSA), the
Berlin Questionnaire was administered; subjects with a positive
score in two or more categories were excluded [13]. Exhaled
nitric oxide (eNO) was measured using portable Niox equip-
ment (Aerocrine Inc., Morrisville, NC, USA) to evaluate whether
CPAP treatment might affect eNO, an index of airway
inflammation. Spirometry was performed using the KoKo1
spirometer (nSpire Health Inc., Longmont, CO, USA) and
subjects with FEV1 ,70% pred were excluded from the study
and no further testing was performed. Those subjects with FEV1
o70% pred performed a bronchial challenge with inhaled MCh
using the five-breath dosimeter protocol recommended by
the American Thoracic Society [14]. Initial inhalation for
the bronchial challenge was saline as a control, followed by
increasing MCh concentrations of 0.0625, 0.25, 1.0, 4.0 and
16.0 mg?mL-1 until there was a fall in FEV1 of 20% from baseline
or the final dose was inhaled. PC20 was calculated by linear
interpolation from the dose–response curve. Subjects who
completed the bronchial challenge at the screening visit without
a 20% decrease in FEV1 by the final dose were excluded from the
study. At the follow-up visit after CPAP or sham treatment, the
bronchial challenge was repeated at the same time of day as the
initial bronchial challenge. Subjects at the follow-up visit who
did not exhibit a 20% decrease in FEV1 with a MCh dose of
16 mg?mL-1 were assigned a PC20 of 32 mg?mL-1.
CPAP and sham treatment
An experienced laboratory technician fitted the subject with an
appropriately sized face mask and instructed the subject on the
use of the equipment. CPAP treatment was set at 8–10 cmH2O,
which depended upon subject tolerance. Sham equipment was
provided by ResMed (Bella Vista, Australia); a leak was created
at the connector to the face mask, which resulted in a mask
pressure between 0 and 2 cmH2O. Subjects used the CPAP or
sham treatment between seven and 10 nights, which included
the night prior to the follow-up assessment of spirometry and
MCh bronchial challenge. The laboratory technician was
available by telephone to address questions related to use of
the face mask and equipment. Use of the CPAP and sham
equipment was evaluated by downloading the recorded
information from machines at the follow-up visit.
Analysis
The primary outcome was comparison of the change in (D)
log transformed PC20 (logPC20) for CPAP- and sham-treated
subjects, which was assessed by an unpaired t-test. Similar
comparisons were performed for FEV1, eNO and Asthma Score.
Demographic characteristics were summarised and compared
between CPAP- and sham-treated subjects using a two-sample t-
test or Pearson’s Chi-squared test as appropriate. We evaluated
DFEV1, DlogPC20 and change in eNO in each group, and
compared the change between two groups using a repeated-
measurement ANOVA model with group (CPAP versus sham),
time (before and after) and their interaction as predictors. A
significant interaction represents a significant difference of
changes between groups. DlogPC20 in each group was tested
in this model too. StatView 5.0.1 (Adept Scientific, Letchworth
Garden City, UK) and SAS 9.3 (SAS Institute Inc., Cary, NC,
USA) were used to conduct all of the analysis.
RESULTS
Subjects
There were 27 subjects (eight males and 19 females) between 19
and 38 yrs of age enrolled into the study; however, two treated
subjects did not return for the follow-up assessment. Table 1
summarises the 25 subjects who completed the study. There
were no significant differences between the CPAP group
(n516) and sham group (n59) for age or sex. Upon entry to the
study, there were no significant differences between the CPAP
and sham groups for use of asthma controller medications
(p50.69), Asthma Score (0.85 versus 0.72, p50.39), FEV1 (86.8
versus 89.6%, p50.46), logPC20 (0.36 versus 0.73, p50.12) or
eNO (48 versus 28, p50.17). All the subjects used CPAP for
o7 days ando4 h per night. In addition, all the subjects used
the CPAP or sham equipment the night before the post-
treatment follow-up visit.
The CPAP group (n516) had a significant decrease in airway
reactivity (DlogPC20 0.406, p,0.0017) while sham group (n59)
had no significant change in airway reactivity (DlogPC20 0.003,
p50.9850) (fig. 1). DlogPC20 with treatment was significantly
greater for the CPAP compared with the sham group (DlogPC20
0.41, p,0.043). In addition, 15 out of 16 subjects in the CPAP
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treatment group demonstrated an increase in PC20 compared
with five out of nine in the sham treatment group; this difference
in the frequency for an increase in PC20 was significant by
Fisher’s exact test (p,0.05).
Neither the CPAP- nor the sham-treated groups demonstrated
a significant change in Asthma Score with treatment and there
was no significant difference for the change in Asthma score
between treatments (fig. 2a and b). None of the subjects
TABLE 1 Demographics
Treatment Subject Age yrs Race Sex Inhaled steroid Leukotriene inhibitor
CPAP 1 27 Caucasian M Y N
CPAP 2 22 Caucasian F N N
CPAP 3 25 Caucasian M N N
CPAP 4 30 Caucasian F N N
CPAP 5 38 Caucasian F Y Y
CPAP 6 26 Caucasian F Y N
CPAP 7 29 Caucasian M N N
CPAP 8 24 Caucasian F N N
CPAP 9 19 Caucasian M Y Y
CPAP 10 21 Non-Caucasian F N N
CPAP 11 29 Non-Caucasian M N Y
CPAP 12 29 Non-Caucasian F N N
CPAP 13 36 Caucasian F Y Y
CPAP 14 24 Caucasian F Y N
CPAP 15 21 Caucasian F Y N
CPAP 16 36 Caucasian F N N
Sham 1 20 Caucasian M Y N
Sham 2 36 Caucasian F Y N
Sham 3 30 Non-Caucasian F Y N
Sham 4 40 Caucasian F N N
Sham 5 48 Caucasian M Y N
Sham 6 24 Caucasian F N Y
Sham 7 25 Caucasian F N N
Sham 8 24 Caucasian M N N
Sham 9 32 Non-Caucasian F Y N
CPAP: continuous positive airway pressure; M: male: F: female; Y: yes; N: no.
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FIGURE 1. Change in log-transformed provocative concentration of methacholine causing a 20% fall in forced expiratory volume in 1 s (PC20) with treatment. logPC20
increased (airway reactivity decreased) significantly with a) continuous positive airway pressure (CPAP) treatment (p,0.004), but not with b) sham treatment (p50.988). The
change in logPC20 was significantly greater for the CPAP compared with the sham group (p,0.043). Solid lines represent individual subjects, and circles and dashed lines
represent group means.
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changed their use of inhaled corticosteroids during the study
period. Similarly, there were no significant changes in FEV1 or
eNO with treatment for either group and there were no
significant differences for the changes in FEV1 or eNO between
treatments (fig. 2c–f).
DISCUSSION
Our study demonstrated that short-term use of nocturnal
CPAP by clinically stable adults with asthma can reduce
airway reactivity, as assessed by MCh bronchial challenge.
These current findings extend to humans our previous work
demonstrating that nocturnal CPAP decreases airway reactiv-
ity in animal models [11]. As heightened airway reactivity is a
phenotypic characteristic of patients with asthma, our study in
adult asthmatics suggests that CPAP has the potential as a
nonpharmacological intervention to decrease airway reactivity.
However, more prolonged treatment will be required to
determine whether CPAP can decrease asthma symptoms
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FIGURE 2. a, b) Change in Asthma Score with treatment. There were no significant changes in Asthma Score with a) continuous positive airway pressure (CPAP)
treatment (p,0.147) or b) sham treatment (p50.594). c, d) Change in forced expiratory volume in 1 s (FEV1) with treatment. There were no significant changes in FEV1 with c)
CPAP treatment (p,0.567) or d) sham treatment (p50.238). e, f) Change in exhaled nitric oxide (eNO) with treatment. There were no significant changes in eNO with e) CPAP
treatment (p,0.326) or f) sham treatment (p50.523). Solid lines represent individual subjects, and circles and dashed lines represent group means. % pred: % predicted.
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and/or the use of medication, which would then make CPAP a
novel therapy for patients with asthma.
We evaluated clinically stable patients with asthma to determine
whether the short-term use of nocturnal CPAP could decrease
airway reactivity, as we had previously observed in an animal
model of allergic pulmonary inflammation [11]. In our animal
studies, we used CPAP of 6 cmH2O, which was well tolerated
and placed the end-expiratory volume (EEV) in the mid-lung
range. As adult humans have stiffer chest walls than rabbits and
ferrets, in the current study, we used CPAP of 8–10 cmH2O,
which should also place EEV above functional residual capacity
and in the mid-lung volume range. In adults with OSA, this
level of CPAP is often the starting pressure for treatment and is
relatively well tolerated by subjects. From our study, we are not
able to determine whether there is a dose–response effect of
CPAP upon airway reactivity.
We screened our subjects to exclude those with a history of OSA;
however, we did not perform sleep studies to confirm the
absence of OSA. As we were primarily interested in the effects of
CPAP upon airway reactivity, we excluded two recruited
subjects who did not respond to our MCh bronchial challenge
protocol with a decrease in FEV1 of 20%. This was done as we
would not have been able to detect a further decrease in airway
reactivity with the abbreviated bronchial challenge protocol we
used. In addition, it would have evaluated subjects with very
low degrees of airway reactivity. For those subjects that received
CPAP or sham treatment, but at follow-up did not respond
during the bronchial challenge with a 20% decrease in FEV1 by a
MCh dose of 16 mg?mL-1, we assigned a PC20 of 32 mg?mL-1.
Although this is an artificial PC20, as this dose was never
delivered, we obtained the same results when a nonparametric
analysis was employed; CPAP-, but not sham-treated, subjects
demonstrated a significant decrease in airway reactivity.
We did not find that nocturnal CPAP changed the Asthma
Score; however, this was not surprising, as we evaluated a
clinically stable group of asthmatics for a relatively short period
of time. Our patient selection created a relatively homogenous
group of clinically stable asthmatics without other significant
health problems. Therefore, we are not able to extrapolate our
findings to subjects with more severe asthma symptoms.
Importantly, we also do not know whether a decrease in airway
reactivity secondary to CPAP treatment has a clinical impact
upon asthma symptoms; this question will require a much
longer period of treatment to evaluate.
We evaluated whether CPAP treatment might alter eNO to
provide some potential insight into its mechanism of action.
Wearing a facemask during sleep could potentially reduce
allergen exposure of the lung during sleep and thus decrease NO
production by decreasing allergic inflammation. Alternatively,
we previously demonstrated that mechanical strain of cultured
bronchial epithelial cells increases nitric oxide production [15].
Therefore, if mechanical strain of the lung by CPAP treatment
increased nitric oxide production, the increased nitric oxide in
the airway could have a bronchoprotective effect upon airway
reactivity [16]. We did not find that CPAP or sham treatment
affected eNO; therefore, alterations in nitric oxide production do
not appear to account for the effect of CPAP on airway reactivity.
CPAP and SHAM treatments had no significant effect upon
FEV1; however, our subjects did not exhibit evidence of severe
airway obstruction, as all subjects had FEV1 .70% pred. A
greater magnitude of chronic mechanical strain or the applica-
tion of CPAP for longer periods of time could potentially initiate
remodelling of the lung. Chronic CPAP treatment for several
weeks has been demonstrated to increase lung volume in
animals, and mechanical strain has been proposed as a potential
treatment for congenital pulmonary hypoplasia [17, 18]. We
previously found that ferrets treated with CPAP of 6 cmH2O not
only increased lung volume, but also increased cross-sectional
area of the conducting airways, when assessed by computed
tomography scan [9]. In these animal studies, there were no
differences in the amount of airway smooth muscle (ASM) in the
airway wall [10], which suggests that the lower airway reactivity
in vivo may be related to the marked plasticity of the contractile
properties of ASM, as well as the airway wall, rather than to a
decrease in the quantity of ASM. The effects of mechanical loads
on the contractility of isolated tracheal muscle tissues in vitro
have been attributed to reorganisation of cytoskeletal and
contractile proteins [19–22]. These processes may be initiated
by mechanosensitive protein complexes that localise to smooth
muscle cell cytoskeletal/extracellular matrix junctions [22–25];
however, it remains unclear whether these processes occur in
vivo, particularly in asthmatic subjects.
There are only a few studies that have previously assessed the
effect of CPAP treatment on airway reactivity in patients with
asthma. LIN et al. [26] used CPAP to evaluate the relatively acute
effects of mechanical strain on airway reactivity. Clinically stable
asthmatics treated with CPAP of 8 cmH2O for 10 min had a
reduction of airway reactivity assessed by bronchial challenge
[26]. Our findings are consistent with those of LIN et al. [26];
however, we greatly extended the CPAP treatment from 10 min
to 1 week. CIFTCI et al. [27] evaluated the effect of CPAP
treatment for 2 months on adults with asthma and OSA. These
investigators selected the level of CPAP to minimise OSA based
upon each subject’s polysomnography (PSG) study. As a group,
there was a significant decrease in asthma night-time symptoms
with 2 months of CPAP treatment and no change in FEV1;
however, airway responsiveness was not assessed and there was
no control or sham treatment group. CHAN et al. [28] evaluated
the effects of a 2-week period of nocturnal CPAP on peak
expiratory flows, asthma symptoms and bronchodilator usage in
nine patients with OSA and unstable asthma. CPAP, compared
with no CPAP, was associated with improvement in pre- and
post-bronchodilator peak expiratory flows, and a decrease in
asthma symptoms, although airway reactivity was not directly
assessed by bronchial challenge testing. In a study of only four
subjects with OSA and airway hyperreactivity assessed by
bronchial challenge, LIN and LIN [29] reported that all four
subjects had a decrease in airway reactivity following 2 months
of CPAP treatment. Lastly, LAFOND et al. [30] evaluated patients
with OSA and stable asthma who were treated for 6 weeks with
a level of CPAP determined by PSG to treat their OSA. These
investigators found that nocturnal CPAP improved the asthma
quality of life score, but there was no effect upon airway
reactivity assessed by bronchial challenge. These studies vary
greatly in study design, types of subjects evaluated, level and
duration of CPAP treatment, and outcome parameters (peak
flow, airway reactivity, asthma symptoms and medication
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usage); however, their cumulative findings, along with our
current study, as well as our pre-clinical animal models, strongly
suggest that CPAP may provide an effective therapy for subjects
with asthma.
In summary, 7 days of nocturnal CPAP decreased airway
reactivity in adults with asthma. Future studies of longer
duration are required to determine whether chronic CPAP can
also decrease asthma symptoms and/or medication usage, as
well as identify asthmatic subjects that can best be treated with
CPAP.
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